| |
| |
| List of Contributors | |
| |
| |
| Preface | |
| |
| |
| |
| Introduction | |
| |
| |
| |
| Concept and Scope of Modern Vaccines | |
| |
| |
| |
| |
| Principles of Vaccine Design | |
| |
| |
| |
| Strategies to Stimulate Innate Immunity for Designing Effective Vaccine Adjuvants | |
| |
| |
| |
| |
| Antigen Processing and Presentation by MHC Class I, II, and Nonclassical Molecules | |
| |
| |
| |
| |
| Understanding the Mucosal Immune System for Better Mucosal Vaccine Design | |
| |
| |
| |
| |
| Immunologic Memory: T Cells in Humans | |
| |
| |
| |
| |
| Immunologic Memory: B cells | |
| |
| |
| |
| |
| Utility of Mouse Models in Vaccine Design and Development | |
| |
| |
| |
| |
| Utility of Nonhuman Primate Models for Vaccines | |
| |
| |
| |
| |
| Antigen Discovery | |
| |
| |
| |
| Sequence-Based Computational Approaches to Vaccine Discovery and Design | |
| |
| |
| |
| |
| Antigen Discovery for Vaccines Using High-throughput Proteomic Screening Technologies | |
| |
| |
| |
| |
| Phage Libraries | |
| |
| |
| |
| |
| Antigen Engineering | |
| |
| |
| |
| Attenuated Bacterial Vaccines | |
| |
| |
| |
| |
| Virus-like Particles as Antigen Scaffolds | |
| |
| |
| |
| |
| Recombinant MVA vaccines: Optimization, Preclinical, and Product Development | |
| |
| |
| |
| |
| Recombinant Adenoviruses for Vaccination | |
| |
| |
| |
| |
| Recombinant Avipoxviruses | |
| |
| |
| |
| |
| Intracellular Facultative Bacterial Vectors for Cancer Immunotherapy | |
| |
| |
| |
| |
| Nucleic Acid Vaccination | |
| |
| |
| |
| |
| Artificial Antigen-presenting Cells: Large Multivalent Immunogens | |
| |
| |
| |
| |
| Delivery Systems | |
| |
| |
| |
| Transcutaneous Immunization via Vaccine Patch Delivery System | |
| |
| |
| |
| |
| Needle-free Jet Injection for Vaccine Administration | |
| |
| |
| |
| |
| Oral Vaccines: An Old Need and Some New Possibilities | |
| |
| |
| |
| |
| Adjuvants: From Serendipity to Rational Discovery | |
| |
| |
| |
| |
| Immunostimulatory Properties of Biodegradable Microparticles | |
| |
| |
| |
| |
| Co-administration of Co-stimulatory Moieties | |
| |
| |
| |
| |
| Toll Receptors in Relation to Adjuvant Effects | |
| |
| |
| |
| |
| Regulatory Considerations | |
| |
| |
| |
| Regulatory Issues (FDA and EMA) | |
| |
| |
| |
| |
| Evaluating Vaccine Efficacy | |
| |
| |
| |
| Immune Monitoring Design within the Developmental Pipeline for an Immunotherapeutic or Preventive Vaccine | |
| |
| |
| |
| |
| Clinical Development Strategy: Nuts and Bolts | |
| |
| |
| |
| |
| Current Approaches to Identify and Evaluate Cancer Biomarkers for Patient Stratification | |
| |
| |
| |
| |
| Implementing Immunizations/Therapies | |
| |
| |
| |
| Mass Immunization Strategies | |
| |
| |
| |
| |
| The Role of Mathematical Models in Vaccine Development and Public Health Decision Making | |
| |
| |
| |
| |
| Vaccine Safety | |
| |
| |
| |
| Index | |